MIT researchers have developed injectable hepatocyte clusters that can survive in mouse tissue for at least two months, producing liver enzymes and proteins without surgical transplantation. The technique, led by Professor Sangeeta Bhatia and postdoc Vardhman Kumar, delivers functional liver cells alongside hydrogel microspheres that behave as a liquid under injection pressure and solidify once inside the body, anchoring the cells and accelerating vascular connection.
The mechanics matter here. The microspheres are not passive scaffolding. Their shear-thinning properties solve a practical problem: how to keep fragile hepatocytes grouped and viable through a syringe needle. Current injection sites target abdominal fat tissue, but the team says other delivery locations are viable. The full paper details the vascularization timeline and protein output data, which is where the real engineering argument lives.
The clinical target is the estimated thousands of Americans with chronic liver disease who cannot tolerate transplant surgery or are waiting on donor organs. Immunosuppression remains an open problem, and the team is pursuing two paths: engineering the hepatocytes to evade immune detection, or loading the microspheres themselves with local immunosuppressants. Neither is solved. That gap is exactly why this paper is worth reading now.
[READ ORIGINAL →]